20June

Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more

03May

Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at c ... Read more

30April

Novo Nordisk to achieve target of 100% renewable power in production and launche ... Read more

26April

Novo Nordisk receives positive opinion from the European regulatory authorities ... Read more

20June

Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU ... Read more

13June

Novo Nordisk A/S - Share repurchase programme ... Read more

29May

Novo Nordisk A/S - Share repurchase programme ... Read more

20May

Novo Nordisk A/S - Share repurchase programme ... Read more

01July

Silent period ,

09August

Financial statement for the first six months of 2019,

16August

Ex-dividend,

19August

Record date,

 

 

 

Investors

Share information

 

Corporate reporting

Private shareholders


Shareholder tools and systems for private investors

 

Investor materials

Contact Investor Relations

Sign-up: Company announcements


Sign up and receive our company announcements

 

Financial results and events overview

SHARE Magazine


Get the latest SHARE Magazine
- news for you as an investor

ADA 2019 event


Access ADA 2019 event
- Webcast and presentation